Management of Chemoradiation-Induced Mucositis in Head and Neck Cancers With Oral Glutamine.

Autor:	Pattanayak L; and Regional Cancer Centre; and SCB Medical College and Hospital, Cuttack, Odisha, India., Panda N; and Regional Cancer Centre; and SCB Medical College and Hospital, Cuttack, Odisha, India., Dash MK; and Regional Cancer Centre; and SCB Medical College and Hospital, Cuttack, Odisha, India., Mohanty S; and Regional Cancer Centre; and SCB Medical College and Hospital, Cuttack, Odisha, India., Samantaray S; and Regional Cancer Centre; and SCB Medical College and Hospital, Cuttack, Odisha, India.
Jazyk:	angličtina
Zdroj:	Journal of global oncology [J Glob Oncol] 2016 Feb 10; Vol. 2 (4), pp. 200-206. Date of Electronic Publication: 2016 Feb 10 (Print Publication: 2016).
DOI:	10.1200/JGO.2015.000786
Abstrakt:	Purpose: Head and neck cancers are the third most common cancers worldwide. Oral mucositis is the most common toxicity seen in patients who receive chemoradiation to treat head and neck cancer. The aim of this study was to evaluate the efficacy and safety of oral glutamine supplementation in these patients. Materials and Methods: From December 2013 to December 2014, we randomly assigned to two arms 162 patients who had squamous cell carcinoma of the head and neck. Patients in arm A were given oral glutamine once per day, whereas those in arm B served as negative control subjects. All patients received radiotherapy given as 70 Gy in 35 fractions over 7 weeks with an injection of cisplatin once per week. Patients were assessed once per week to evaluate for the onset and severity of mucositis, pain, use of analgesics, and for Ryle tube feeding. Results: We observed that 53.1% of patients developed mucositis toward the fifth week in the glutamine arm compared with 55.5% of patients in the control arm at the third week. None in the glutamine arm compared with 92.35% of patients in the control arm developed G3 mucositis. Rates of adverse events like pain, dysphagia, nausea, edema, and cough, as well as use of analgesics and Ryle tube feeding, were significantly lower in the glutamine arm than in the control arm. Conclusion: This study highlights that the onset as well as the severity of mucositis in patients receiving glutamine was significantly delayed. None of the patients receiving glutamine developed G3 mucositis. Hence, the findings emphasize the use of oral glutamine supplementation as a feasible and affordable treatment option for mucositis in patients with head and neck cancers who are receiving chemoradiation. Competing Interests: Authors' disclosures of potential conflicts of interest and contributions are found at the end of this articleManagement of Chemoradiation-Induced Mucositis in Head and Neck Cancers with Oral GlutamineThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc. Lucy Pattanayak No relationship to disclose Niharika Panda No relationship to disclose Manoj Kumar Dash No relationship to disclose Sumita Mohanty No relationship to disclose Sagarika Samantaray No relationship to disclose
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu